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Abstract 
Background: Breast cancer subtype, determined by expression of estrogen/progesterone receptor (ER/PR) and 
human epidermal growth factor receptor (HER)‑2, is predictive for prognosis. The importance of subtype to locore‑
gional recurrence (LRR) following neoadjuvant chemotherapy (NAC) is unknown, particularly after adjuvant radio‑
therapy (RT).
Methods: We retrospectively identified 160‑breast cancer patients registered at Columbia University Medical Center 
from 1999 to 2012 treated with NAC, surgery and adjuvant RT.
Results: Patients were grouped by receptor status: hormone receptor positive (HR+) [(ER or PR+)/HER2−; n = 75], 
HER2+ (n = 46), or triple‑negative (TNBC) [ER (−) PR (−) HER2 (−); n = 36]. The median follow‑up was 28 months. 
92.0% received an anthracycline‑taxane based NAC and 80.4% of HER2+ patients received trastuzumab. All under‑
went surgical resection followed by RT. 15.6% had a pathologic complete response (pCR): 26% of HER2+, 5% of HR+, 
and 25% of TN. The actuarial rate of DM was 13.8% for the entire cohort, with equivalent rates by subtypes in non‑pCR 
patients. The overall rate of LRR was 8%. However, the LRR rate was significantly higher for TNBC patients (22.2%) than 
HER2+ (5.6%) (p = 0.025) or HR+ (3.0%) (p = 0.037) in non‑pCR group. In the pCR group, two patients had recur‑
rence; one LRR and one a DM, both had TNBC. All LRR occurred in or near the radiation field.
Conclusions: TNBC patients with < pCR to NAC have a significantly higher LRR rate as compared to other subtypes 
even with surgery and adjuvant RT. Our data support a need to further intensify local therapy in TNBC patients.
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Background
Triple-negative breast cancers (TNBC), i.e., tumors neg-
ative for ER, PR and HER2, comprise 15–20% of breast 
cancers in the United States but account for a dispropor-
tionate share of morbidity and mortality (Boyle 2012). 
Gene expression studies using microarrays have iden-
tified four common subtypes of breast cancer that are 
not apparent using traditional histopathologic methods: 
luminal A, luminal B, HER2 positive, and basal-type 
(Perou et al. 2000; Sorlie et al. 2001, 2003). Most TNBCs 
are high-grade invasive ductal carcinomas, approximately 
80% of which display a basal-like pattern when analyzed 
by gene expression (mRNA) microarray (Rakha et  al. 
2008; Lehmann et al. 2011). A fraction (>60%) of tumors 
with borderline ER expression (1 to 10%) is also classified 
as basal-like (Deyarmin et al. 2013).
TNBC predicts for poorer overall survival (OS) and 
distant metastasis (DM) following treatment (Abdulka-
rim et  al. 2011; Haffty et  al. 2006; Nguyen et  al. 2008; 
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Dent et  al. 2007). Whether TNBC is associated with 
higher rates of locoregional recurrence (LRR) is contro-
versial, previous studies combined patients with or with-
out adjuvant RT and reported rates of LRR from 4 to 29% 
(Abdulkarim et al. 2011; Haffty et al. 2006; Nguyen et al. 
2008; Dent et al. 2007; Millar et al. 2009; Dominici et al. 
2012; Liedtke et  al. 2008). Neoadjuvant chemotherapy 
(NAC) is increasingly being used in women with locally 
advanced breast cancer or high-risk early stage disease 
(White and Mamounas 2014). Numerous reports on the 
chemosensitivity, and prognosis of different subtypes of 
breast cancers to NAC have been published with poorer 
overall outcome again observed in TNBCs (Rouzier et al. 
2005; Meyers et  al. 2011; Esserman et  al. 2012; Rastogi 
et al. 2008; Mieog et al. 2007; von Minckwitz et al. 2012; 
Berry et  al. 2006; Hugh et  al. 2009; Saigal et  al. 2013; 
Caudle et al. 2012; Carey et al. 2007; Nielsen et al. 2004). 
Nonetheless, the correlation between subtypes of breast 
cancer and rates of LRR in the setting of NAC is not well 
characterized. We thus have conducted a single institu-
tional retrospective study comparing the LRR rate of 
TNBCs with other subtypes of breast cancer for patients 
treated with trimodality therapy: NAC, surgery and all 
with adjuvant RT.
Methods
End points and statistical methods
LRR was defined as first site of failure being locoregional 
to primary site, which includes the chest wall/intact 
breast, ipsilateral axilla, internal mammary nodes, or 
SCV fossa. Progression-free survival (PFS) was defined as 
the time from the date of surgery to earliest occurrence 
of LRR or DM. Overall survival (OS) was defined as the 
time from diagnosis to date of death due to any cause. A 
pCR to NAC was defined as no residual invasive disease 
in the breast or axilla at surgery.
All statistical analyses were conducted with SPSS soft-
ware (IBM SPSS 21) and SAS software 9.2. Rates of LRR-
free, progression-free, and overall survival (OS) were 
calculated by the Kaplan–Meier method, with compari-
sons among groups performed with log-rank tests. Cox 
regression analyses were used for multivariate analysis. 
Chi-squared or Fisher’s exact tests were used for analy-
sis with categorical variables. All P values were two-sided 
with α = 0.05.
Patient population
This study was conducted under an institutional review 
board approved protocol (IRB-AAAJ8512) at Columbia 
University Medical Center. A waiver for consent to par-
ticipate was granted for all patients involved by the IRB 
for this retrospective studies. Under this approved pro-
tocol (IRB-AAAJ8512), we retrospectively identified all 
breast cancer patients registered at Radiation Oncol-
ogy at CUMC from 1999 to 2012. Only patients who 
were treated with NAC, surgery and adjuvant RT were 
included.
Breast cancer subtype classification
Basal-like subtype was largely hormonal receptor nega-
tive (HR−) (ER−/PR−and HER2−, the HER2 enriched 
subtype was HR− and HER2+, and the luminal sub-
type (luminal A and B combined) was ER+ (Carey et al. 
2007; Nielsen et al. 2004). For this study, three subtypes 
are defined: (1) Hormonal receptor positive (HR+) (ER+ 
and/or PR+), and HER2/neu non-amplified (HER2−) 
tumors representing luminal types (luminal A and the 
majority of luminal B); (2) HER2+ tumors representing 
HER2 enriched and a minority of luminal B; (3) Triple 
negative (ER−, PR−, and HER2−) breast cancers rep-
resenting basal-like tumors. Tumors were considered 
HER2+ if they were 3+ by IHC or positive for HER2/neu 
gene amplification by fluorescence in situ hybridization.
Results
Demographics
Table  1 illustrates the patient characteristics and the 
treatments of the tumors applied. 160 patients were 
treated with NAC, surgery and adjuvant RT diagnosed 
between year 1999 and 2012. 75 patients had HR+/
HER2− tumors, 46 patients had HER2+ tumors and 36 
patients had TNBCs. Three patients had no HER2 status 
reported thus were not grouped into either of the sub-
types. Of the 46 patients with HER2+ disease, 9 were 
HR+/HER2+ with the rest HR−/HER2+. Median age at 
diagnosis was 52 years, not significantly different among 
the three subtypes. Our cohort had a high percentage 
of black and Hispanic patients, all together 44.4% (16.9 
and 27.5% respectively). The percentage was even higher 
for TNBCs, 58.4% black and Hispanic (27.8 and 30.6% 
respectively).
62.5% of the cohort received Adriamycin/Cyclophos-
phamide/Taxol (AC/T) as NAC while 31.2% had AC 
only, T only, CMF or other types. Patients with TNBCs 
had a significantly higher rate (77.8%) of receiving AC/T 
backboned NAC than other subtypes (p =  0.04). 80.4% 
of HER2+ patients received Trastuzumab. 27.5% patients 
had lumpectomy following NAC. 71.3% had modified 
radical mastectomy including 16 cases of skin or nipple 
sparing mastectomy.
All patients received RT, for 144 patients (90%) all 
details of RT setups are known. All patients had radia-
tion to chest wall after mastectomy or the whole breast 
after lumpectomy. 78.1% patients received regional nodal 
irradiation covering axillary and supraclavicular nodes 
using three- or four-field technique, including 8.1% of 
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Table 1 Demographics and tumor characteristics
* P values were calculated with the unknown or unspecified group excluded. All P-values were calculated using Pearson’s Chi-squared tests.
a Two patients had only axillary nodal dissection due to no clinical evidence of primary cancer found in the breast.
b Three patients presented with likely stage IV disease with one patient having lung nodules on CT scan, one with adrenal uptake and the other patient with sternal 
uptake on PET scan, all resolved after NAC, thus were treated definitively afterward.
Variables Total HR+/HER2− HER2+ TN P
Age at diagnosis, median (range) 52 years (25–85) 52 (26–85) 50 (27–73) 50 (31–84)
 ≤50 years 75 (46.9%) 33 (44.0%) 23 (50.0%) 19 (52.8%) 0.64
 >50 years 85 (53.1%) 42 (56.0%) 23 (50.0%) 17 47.2%)
Race/ethnicity
 White, non‑Hispanic 59 (36.9%) 29 (38.7%) 19 (41.3%) 9 (25.0%) 0.29
 Black, non‑Hispanic 27 (16.9%) 10 (13.3%) 7 (15.2%) 10 (27.8%)
 Hispanic 44 (27.5%) 18 (24.0%) 14 (30.4%) 11 (30.6%)
 Other or unknown 30 (18.8%) 18 (24.0%) 6 (13.0%) 6 (16.7%)
Laterality
 Left 80 (50.0%) 42 (56.0%) 20 (43.4%) 17 (47.2%) 0.42
 Right 79 (49.4%) 33 (44.0%) 25 (54.3%) 19 (52.8%)
 Bilateral 1 (0.6%) 0 (0%) 1 (2.2%) 0 (0%)
Pathology
 IDC 128 (80.0%) 52 (69.3%) 40 (87.0%) 33 (91.7%) 0.02
 ILC 15 (9.4%) 13 (17.3%) 1 (2.2%) 1 (2.8%)
 Mixed 14 (8.8%) 8 (10.7%) 5 (10.9%) 1 (2.8%)
 Other 3 (1.9%) 2 (2.7%) 0 (0%) 1 (2.8%)
Chemotherapy
 chemo (AC/T backbone) 100 (62.5%) 46 (61.3%) 25 (54.3%) 28 (77.8%) 0.04*
 non‑AC/T backbone 50 (31.2%) 23 (30.7%) 20 (43.4%) 6 (16.7%)
 Unspecified 10 (6.2%) 6 (8.0%) 1 (2.2%) 2 (5.6%)
Trastuzumab received
37 of 46 (80.4%) N/A 37 of 46 (80.4%) N/A N/A
Surgery
 Mastectomy 114 (71.3%) 59 (78.7%) 32 (69.6%) 22 (61.1%) 0.23
 Lumpectomy 44 (27.5%) 15 (20.0%) 14 (30.4%) 14 (38.9%)
 ALND onlya 2 (1.3%) 1 (1.3%) 0 (0%) 0 (0%)
Radiation
 Breast only (2 fields) 19 (11.9%) 7 (9.3%) 6 (13.0%) 6 (16.7%) 0.51
 CW/breast + axillary + SCV LNs (3 or 4 fields) 112 (70.0%) 52 (69.3%) 32 (69.6%) 25 (69.4%)
 CW/breast + axillary + SCV + IMN (deep tangents or 5 fields or IMRT) 13 (8.1%) 5 (6.7%) 4 (8.7%) 4 (11.1%)
 Unspecified 16 (10.0%) 11 (14.7%) 4 (8.7%) 1 (2.8%)
 Boost to tumor cavity and/or scar 91 (56.9%) 43 (57.3%) 21 (45.6%) 27 (75.0%) 0.03
Stage (clinical)
 I 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.46*
 II 78 (48.8%) 38 (50.7%) 19 (41.3%) 20 (55.6%)
 III 71 (44.3%) 31 (41.3%) 23 (50.0%) 15 (41.7%)
 IVb 3 (1.9%) 1 (1.3%) 2 (4.3%) 0 (0%)
 Unknown 8 (5.0%) 5 (6.7%) 2 (4.3%) 1 (2.8%)
Stage (pathologic)
 pCR (total) 25 (15.6%) 4 (5.3%) 12 (26.1%) 9 (25.0%) 0.001
 T0 19 (11.9%) 4 (5.3%) 8 (17.4%) 6 (16.7%)
 Tis 6 (3.7%) 0 (0%) 4 (8.7%) 3 (8.3%)
 I 25 (15.6%) 8 (10.7%) 10 (21.7%) 7 (19.4%) 0.07*
 II 49 (30.6%) 26 (34.7%) 10 (21.7%) 12 (33.3%)
 III 59 (36.9%) 37 (49.3%) 12 (26.1%) 8 (22.2%)
 IV 1 (0.6%) 0 (0%) 1 (2.2%) 0 (0%)
 Unknown 1 (0.6%) 0 (0%) 1 (2.2%) 0 (0%)
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patients with internal mammary nodes irradiated. TNBC 
patients had a higher rate (75%) of receiving boost RT to 
scar or tumor cavity than the other subtypes (p = 0.03). 
The majority of patients were treated using 3D conformal 
radiation techniques with only 5% treated with inverse 
planning intensity modulated radiation therapy (IMRT).
Response to NAC
A majority of the patients presented with clinical stage 
II and III cancer (Table  1). Down staging of the disease 
was observed after NAC. 25 patients (15.6%) achieved 
pCR with no invasive disease identified from surgery in 
primary breast or axilla. HR+/HER2− patients had sig-
nificant lower ratio of achieving pCR (5.3%) compar-
ing with HER2 + (26.1%) (p = 0.001) and TNBCs (25%) 
(p = 0.003). Another 25 (15.6%) patients had pathologic 
stage I disease after NAC, again with a much lower rate 
(about half ) in HR +/HER2- subtype comparing with the 
other two subtypes.
Treatment outcomes and survivals
After a median follow-up of 28  months 
(5  months–13.7  years), the 3-year OS was 85.4%; the 
3-year progression-free survival (PFS) was 68.5%. The 
3-year OS was 100% for patients who achieved pCR 
after NAC compared to 82.7% for patients without pCR 
(p = 0.06). The 3-year PFS was 87.5% for pCR vs. 65.2% 
for non-pCR patients (p = 0.08). Only one patient (cT2 
cN1 M0) with pCR had LRR that occurred 26  months 
after finishing RT. Another patient (cT2 cN3 M0) with 
pCR had DM to the brain 2 months after RT. Both had 
TNBC, received AC/T followed by lumpectomy and 
axillary lymph node dissection. The patient with LRR 
had RT to the whole breast while the patient with DM 
received RT to whole breast, full axillary and supracla-
vicular nodes. Patients with non-pCR had poorer prog-
nosis with a total of 11 LRRs including two patients with 
concurrent LRR and DM, and 19 patients with DM as the 
first site of failure. For the entire cohort, LRRs occurred 
within 29 months after surgery (median time to LRR was 
13 months).
In the overall cohort, significantly higher rate of LRR 
was shown in TNBCs (19.4%) compared to HR+/HER2− 
(5.33%) (p  =  0.037) and HER2+ (2.18%) (p  =  0.019) 
(Table  2). The difference was even more prominent for 
non-pCR patients. LRR rate in TNBCs was 22.2 vs. 5.6% 
in HR+/HER2− (p = 0.025) and 2.9% in HER2+ groups 
(p  =  0.037). Interestingly, no significant difference was 
found in DM among the subtypes as the first site of fail-
ure (p = 0.73).
The above analyses were conducted by defining HR− as 
both ER <1% and PR <1% based on the current standard 
(Hammond et al. 2010). Due to reports that weakly ER/
PR+ disease harbors a significant portion of basal-like 
tumors (Deyarmin et  al. 2013), we reanalyzed the LRR 
rates redefining TNBC subtype as being both ER and PR 
<10% and HER2− (Table 2). The results showed two addi-
tional cases of LRR in the TNBCs (<10%) as additional 7 
cases (originally in HR+/HER2− group) were included 
in the redefined TNBC subtype. The redefined TNBCs 
(<10%) had even higher rate (23.5%) of LRR in non-
pCR patients when comparing to HR+/HER2− (3.3%) 
(p  =  0.003) and HER2+ subtypes (2.9%) (p  =  0.027). 
In non-pCR group, the highest rate of DM was seen in 
TNBCs (20.6%), compared with HR+/HER2− (14.8%) 
and HER2+ subtypes (14.7%) but the difference did not 
reach statistical significance (p  =  0.41 and p  =  0.75, 
respectively). No statistically significant difference was 
found among the subtypes of the crude death rate for the 
entire cohort or non-pCR patients by definition of HR 
<1% or <10%.
We reviewed the radiation field setup and individual 
RT plans delivered to all patients with LRR. The pattern 
of failure was summarized in Table 3. All LRRs occurred 
either in or near radiation fields. The only LRR in the 
pCR group occurred 28  months after lumpectomy and 
whole breast RT (5,000 cGy followed by 1,000 cGy boost 
to tumor bed). The patient recurred with a skin nodule 
in the inframammary fold within the RT field but not 
near the lumpectomy margin. Of the 11 LRRs in non-
pCR patients, seven occurred in the intact breasts (after 
lumpectomy) or chest wall (after mastectomy) and four 
of them occurred in the irradiated regional nodal area.
Using Kaplan–Meier analyses, we have further com-
pared the LRR-free, DM-free, Progression-free and 
overall survivals among different subtypes in non-
pCR patients (Fig.  1). Log-rank studies showed sig-
nificantly higher risk of LRR in TNBCs (HR <1%) 
comparing to HR+/HER2− (p  =  0.033) and HER2+ 
subtypes (p = 0.02). DM-free survival curve showed rela-
tively early onset of DM in TNBCs but the difference was 
not significant among subtypes (p = 0.6). PFS again did 
not show statistically significant difference among sub-
types (p = 0.2) likely due to similar DM rates in different 
subtypes. Median OS time has not been reached in our 
study. Although the 3- or 5-year OS rates among differ-
ent subtypes are not different significantly, it is noted that 
HER2+ patients have relatively later occurrence of death.
14 patients were identified among the 160 in our data-
base with inflammatory breast cancer (IBC); two with 
stage IV and the remaining stage III at diagnosis. 8/14 
have HER2+ disease, 5/14 are HR+ (>1%)/HER2-, and 
one patient with TNBC (HR <1%). 13/14 had modi-
fied radical mastectomy, one patient had no ALND per-
formed due to chest wall and nerve involvement of the 
tumor and eventually had local recurrence in chest wall. 
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All patients received adjuvant RT to chest wall and axilla 
(ranging from 5,000 to 5,040  cGy) and SCV (4,500–
5,040  cGy), with seven patients receiving boost dose of 
RT to the scar (1,000–2,000  cGy). Three patients had 
LRR, including the patient with TNBC; the other two had 
HR+ (<10%)/HER2− and HER2+ disease. Five patients 
had DM as first relapse, three with HR +/HER2- and two 
with HER2+ disease. Seven patients died over a median 
of 29 months after diagnosis (range 11.9–55.6).
Risk factors for LRR
Univariate analysis (UVA) of the patients’ and tumor 
characteristics showed the following factors predicting 
higher risk of LRR: subtype (p  =  0.019), race/ethnicity 
(p = 0.014), surgical pathologic grade (post-neoadjuvant 
chemotherapy) (p = 0.005) and lymphovascular invasion 
(LVI) (p =  0.021). Age (≤50 vs. >50  years) (p =  0.068), 
clinical staging (p  =  0.24), pathologic stage (p  =  0.31), 
mitotic index (p  =  0.29), type of chemotherapy 
(p =  0.75), margin status (p =  1.0) and grade of tumor 
from biopsy (pre-NAC) (p = 0.34) did not show signifi-
cant correlations with higher risks of LRR per UVA. Mul-
tivariate analysis (MVA) confirmed that TNBCs were 
associated with significantly higher risk of LRR with haz-
ard ratio (HR) being 3.33 compared with non-TNBCs 
(95% confidence interval (CI) 1.04–10.70, p  =  0.043) 
(Table  4). With LRR and DM included in PFS calcula-
tions, TNBCs was again seen with worse PFS (HR 1.94, 
CI 0.92–4.09) but results from MVA were not statistically 
significant (p =  0.083). There was a significantly higher 
risk of LRR (p =  0.014) and progression (p =  0.001) in 
patients with high grade of tumor at surgery in MVA.
Discussion
Numerous studies have reported that TNBC is associ-
ated with a poor prognosis. Recently, more attention has 
been paid to patients receiving neoadjuvant chemother-
apy (NAC). Whether the rate of LRR in certain subtypes 
Table 2 Incidences of LRR, DM and death from all causes among different subtypes
Triple negative breast cancer was defined as ER and PR positive staining either in <1% cells or in <10% cells as shown respectively.
All LRR and DM are counted as first site of failure.
** P values are obtained using Fisher’s exact tests with two degree-of-freedom.
╥ P values are calculated using Fisher’s exact tests comparing with TN subtype.
a There were three patients who had no HER2 status documented.
b Two of the LRR occurred simultaneously with DM.
Events Incidences Subtypes P**
TNBC is defined as ER/PR positive staining in <1% cells
Alla (n = 157) HR+/HER2− (ER/PR ≥1%) (n = 75) HER2+ (n = 46) TN (ER/PR <1%) (n = 36) P
 LRR 12b (7.6%) 4 (5.3%) (p = 0.037)π 1 (2.2%) (p = 0.019)π 7 (19.4%) 0.014
 DM 22 (14.0%) 11 (14.7%) (p = 0.78)π 5 (10.9%) (p = 0.52)π 6 (16.7%) 0.73
 Death 21 (13.4%) 8 (10.7%) (p = 1.0)π 7 (15.2%) (p = 0.75)π 4 (11.1%) 0.77
Non‑pCR (n = 132) HR+/HER2− (ER/PR ≥1%) (n = 71) HER2+ (n = 34) TN (ER/PR <1%) (n = 27) P
 LRR 11 (8.3%) 4 (5.6%) (p = 0.025)π 1 (3.0%) (p = 0.037)π 6 (22.2%) 0.023
 DM 21 (15.9%) 11 (15.5%) (p = 0.76)π 5 (14.7%) (p = 0.74)π 5 (18.5%) 0.90
 Death 19 (14.4%) 8 (11.3%) (p = 0.73)π 7 (20.6%) (p = 0.74)π 4 (14.8%) 0.40
TNBC is defined as ER/PR positive staining in <10% cells
Alla (n = 157) HR+/HER2− (ER/PR ≥10%) (n = 68) HER2+ (n = 46) TN (ER/PR <10%) (n = 43) P
 LRR 12b (7.6%) 2 (2.9%) (p = 0.003)π 1 (2.2%) (p = 0.006)π 9 (20.9%) 0.001
 DM 22 (14.0%) 9 (13.2%) (p = 0.59)π 5 (10.9%) (p = 0.37)π 8 (18.6%) 0.59
 Death 21 (13.4%) 5 (7.3%) (p = 0.21)π 7 (15.2%) (p = 1.0)π 7 (16.3%) 0.27
Non‑pCR (n = 132) HR+/HER2− (ER/PR ≥10%) (n = 64) HER2+ (n = 34) TN (ER/PR< 10%) (n = 34) P
 LRR 11 (8.3%) 2 (3.3%) (p = 0.003)π 1 (2.9%) (p = 0.027)π 8 (23.5%) 0.002
 DM 21 (15.9%) 9 (14.8%) (p = 0.41)π 5 (14.7%) (p = 0.75)π 7 (20.6%) 0.68
 Death 19 (14.4%) 5 (7.8%) (p = 0.10)π 7 (20.6%) (p = 1.0)π 7 (20.6%) 0.11
Table 3 Pattern of failure and locations of LRR
a This patient had brain metastasis 2 months after RT (5 months after surgery).
b Lung metastases 9, brain 6, bone 4, Liver 4, contralateral axilla 1, retrosternal 1. 
A few patients had simultaneous DM in multiple organs.
LRR DM
In-field Near-field Out-field
pCR 1 0 0 1a
Non‑PCR 10 1 0 21b
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of breast cancer is higher, particularly in TNBCs, is 
unknown, partly due to the heterogeneity of patients 
and their treatment regimens reported in prior studies 
(Abdulkarim et al. 2011; Haffty et al. 2006; Nguyen et al. 
2008; Dent et al. 2007; Millar et al. 2009; Dominici et al. 
2012; Liedtke et al. 2008; Rouzier et al. 2005; Panoff et al. 
2011; Bauer et al. 2007). In our patient cohort comprised 
mainly of clinical stage IIb to III disease, every patient 
received a course of NAC, surgery and radiation. About 
two-thirds of the patients (62.5%) received AC/T back-
boned NAC. The majority of patients had mastectomy 
(71.3%). 78.1% patients received extensive RT covering 
chest wall or intact breast, axillary and supraclavicular 
nodes.
Fig. 1 Comparisons of survivals between subtypes in non‑pCR patients. a Locoregional‑recurrence‑free survival (LRR‑Free Survival). b Distant‑
metastasis‑free survival (DM‑Free Survival). c Progress‑free survival. d Overall survival. P values shown here are from comparisons among all three 
subtypes.
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Our retrospective study revealed that TNBCs are asso-
ciated with significantly increased LRR rate compar-
ing to other subtypes. Our data showed an accumulated 
incidence of 19.2% LRR in TNBCs, much higher than 
other subtypes (4.1% in non-TNBC group). Results were 
significant by UVA and MVA. All LRRs occurred within 
28 months after surgery (median time to LRR in TNBC 
group is 3.6 vs. 5 months in non-TNBCs, p > 0.05). The 
overall DM (first site of failure) rates were similar among 
subtypes. The LRR rate of TNBCs in our patient popu-
lation is slightly higher compared to the other stud-
ies. For example, the studies from Caudle et  al. showed 
10.5% 5-year LRR in TNBCs after NAC, lumpectomy 
and adjuvant RT while only 3% in luminal A type (Cau-
dle et al. 2012). The relatively higher percentage of lower 
clinical stages at presentation (71% clinical stage I/II 
disease) in that study may explain the low incidence of 
LRR. Another study from University of North Carolina 
reported an overall 14% LRR rate of TNBCs but only 4% 
in non-TNBCs with a median follow up of 55  months 
(Meyers et  al. 2011). However, not all patients in these 
studies received adjuvant RT.
Another explanation for the higher incidence of LRR 
in our data may be the significantly higher proportion 
of non-White patients in our cohort, which is not seen 
in other studies (Meyers et al. 2011; Caudle et al. 2012). 
44.4% patients in our study were non-White, including 
black non-Hispanic (16.9%) and Hispanic (27.5%), while 
36.9% are White non-Hispanic. The study from Meyers 
et al. (2011) included a much higher proportion of White 
patients (62%). Patients with TNBCs are significantly 
more likely to be African Americans and Hispanics and 
this is reported to confer worse prognosis, including 
mortality (Deyarmin et al. 2013; Carey et al. 2006; Lund 
et al. 2009; Vona-Davis and Rose 2009; Maskarinec et al. 
2011; Wu et al. 2013). We have confirmed this finding by 
showing a significant difference of cumulative mortality 
in our Hispanic (27.3%), black non-Hispanic (14.8%) and 
white non-Hispanic group (6.8%) (p  =  0.02) (Table  5). 
In addition, a significantly higher cumulative incidence 
of LRR was seen in black non-Hispanic patients (22.2%) 
comparing to white non-Hispanics (p  =  0.02), cor-
relating with the higher rate of mortality. This was not 
observed in Hispanic patients, LRR rate 6.8 vs. 5.1% in 
White non-Hispanics (p  =  1.0). The LRR reached an 
exceptionally high rate of 40% in black non-Hispanic 
patients with TNBCs, with four incidences out of a total 
of ten patients. The LRR rate in Hispanic patients with 
TNBCs was 18%, with two incidences out of a total of 11 
patients. The LRR rate in White non-Hispanics was 11%, 
with one LRR out of a total of nine patients. Hispanic 
patients showed a somewhat higher rate of DM than 
the other groups but the difference was not statistically 
significant. Overall, our data suggested that both black 
and Hispanic patients had worse prognosis in survival 
than White non-Hispanic patients, consistent to pre-
vious reports. We have, for the first time, reported the 
significantly increased risk of LRR in black non-Hispanic 
patients, particularly high in black non-Hispanics with 
TNBCs (40% LRR).
Table 4 Cox regression analyses on LRR and PFS
a This includes grade 1, 2 and the patients who had pCR after NAC.
MVA variants LRR PFS
Hazard ratio (95%CI) P Hazard ratio (95%CI) P
TN vs. not TN 3.33 (1.04–10.70) 0.043 1.94 (0.92–4.09) 0.083
Surgical pathologic grade
 Grade 3 vs. othera 6.93 (1.48–32.53) 0.014 3.70 (1.66–8.22) 0.001
 Age >50 vs. ≤50 years 0.46 (0.12–1.77) 0.26 0.91 (0.43–1.94) 0.81
Table 5 Incidences of LRR, DM and death among different races/ethnicities
** P values are calculated via Fisher’s exact tests, two degree-of-freedom, without the “other and unknown” group.
╥ P values are calculated using Fisher’s exact tests comparing with White non-Hispanic.
a Other and unknown: 24 patients self-identified as other, three are Asians, and three are unknown.




Hispanic (44) Other and  
unknowna (30)
P**
LRR 12 (7.5%) 3 (5.1%) 6 (22.2%) (p = 0.02)╥ 3 (6.8%) (p = 1.0)╥ 0 (0%) 0.04
DM 22 (13.8%) 8 (13.6%) 3 (11.1%) (p = 1.0)╥ 10 (22.7%) (p = 0.30)╥ 1 (3.3%) 0.39
Death 21 (13.1%) 4 (6.8%) 4 (14.8%) (p = 0.25)╥ 12 (27.3%) (p = 0.006)╥ 1 (3.3%) 0.02
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Deyarmin et  al. recently showed that low-ER-staining 
(1–10%) tumors were clinicopathologically more similar 
to ER-negative than to ER-positive tumors (Deyarmin 
et al. 2013). Using molecular subtyping, 62% of the low-
staining tumors were classified as basal like and 27% as 
HER2 enriched. In our study, the rate of LRR in TNBC 
group was more prominent if using the definition of hor-
monal receptor positivity being ≥10% of stained cells 
instead of the ASCO/CAP guideline of being ≥1%. The 
crude relative risks of LRR of TNBCs vs. non-TNBCs 
increased from 4.7 (HR <1%) to 7.9 (HR <10%). Our data 
may serve as an indirect evidence to support the claim 
of Deyarmin et  al. that “10%” could be a more accurate 
threshold to define ER-positivity.
Further followup of patients with LRR revealed that 
local failure led to high risk of DM and cancer-specific 
death. Of the ten patients with LRR as the only site of first 
failure, eight developed DM with a median time interval 
of 7 months after LRR (range 1–12 months). One patient 
was lost to follow up after treatment and the other one 
had a suspicious bony metastasis but lost to follow up 
before DM was confirmed. Two of the eight patients 
(25%) died shortly after DM was diagnosed (both within 
1  month). Our results indicate the importance of the 
locoregional control for improving overall prognosis.
After NAC, 15.6% patients overall achieved pCR. 
Among them, 25% TNBCs had pCR while only 5.3% in 
HR+/HER2− group had pCR, consistent to other reports 
that luminal A responded less to NAC comparing to 
other subtypes (Meyers et  al. 2011; Rastogi et  al. 2008; 
Mieog et al. 2007). In TNBCs, higher percentage (38.9%) 
received lumpectomy likely due to better response to 
NAC. However, we do not think that lumpectomy con-
tributes to higher rate of LRR. Only one patient out of a 
total of 14 after lumpectomy developed LRR, while six 
LRR (3 locally, 2 locoregionally and 1 in regional nodes) 
occurred out of 23 TNBCs after mastectomy (p = 0.22). 
Our results indicated that lumpectomy is a valid surgical 
approach for TNBC patients without risks of increasing 
LRR in selected patients with good responses to NAC.
Conclusion
In conclusion our study is the first to report an increased 
risk for LRR in TNBC patients following NAC in a cohort 
in which all patients received adjuvant RT. The risk of 
LRR is particularly high in African Americans with 
TNBC. The majority of patients received RT to chest 
wall/breast and regional lymph nodes, with more than 
half (including the majority of TNBC patients) receiv-
ing an additional boost dose of RT to the tumor bed and/
or surgical scar. In spite of adjuvant RT, the incidence of 
LRR in TNBCs remains high. TNBC are reported to have 
an enriched content of cancer stem cells, which likely 
convey higher radioresistance (Atkinson et al. 2013), this 
may explain the high rate of LRR in those with <pCR. 
Given the importance of locoregional control in prevent-
ing future DM, our data indicate the need for intensifica-
tion of therapy in TNBCs with <pCR to NAC. Options 
include adding radiosensitizing agents during radiation 
course and/or additional adjuvant chemotherapy after 
surgery. Identification of potential resistant subgroups 
of TNBCs to RT will also shed light on how to pre-select 
patients for treatment intensification.
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